| Names | |
|---|---|
| Preferred IUPAC name (Pyridin-3-yl)methyl ({4-[(2-aminophenyl)carbamoyl]phenyl}methyl)carbamate | |
| Other names SNDX-275; MS-275 | |
| Identifiers | |
3D model (JSmol) | |
| ChEBI | |
| ChEMBL | |
| ChemSpider |
|
| ECHA InfoCard | 100.158.999 |
| KEGG |
|
| UNII | |
| |
| |
| Properties | |
| C21H20N4O3 | |
| Molar mass | 376.4085 g/mol |
| Pharmacology | |
| L01XH05 (WHO) | |
Except where otherwise noted, data are given for materials in theirstandard state (at 25 °C [77 °F], 100 kPa). | |
Entinostat, also known asSNDX-275 andMS-275, is abenzamidehistone deacetylase inhibitor undergoing clinical trials for treatment of various cancers.[1][2][3][4]
Entinostat inhibits class IHDAC1 andHDAC3 withIC50 of 0.51 μM and 1.7 μM, respectively.[5]
Syndax pharmaceuticals currently holds the rights to entinostat and recently received $26.6 million in funds to advance treatments of resistant cancers using epigenetic tools.[6]
It has also been investigated as a potentialmale contraceptive drug.[7]
Thisantineoplastic orimmunomodulatorydrug article is astub. You can help Wikipedia byexpanding it. |